Powered by

Janssen taps South Korea's Yuhan for Tagrisso rival

Nov 06, 2018 - FierceBiotech

South Korean pharma Yuhan has licensed its lung cancer drug lazertinib to Janssen Biotech for $50 million upfront and another $1.2 billion in milestones.

The drug, billed as a third-generation EGFR tyrosine kinase inhibitor, has already generated positive results in a phase 1/2 non-small cell lung cancer (NSCLC) trial reported at this year's ASCO meeting.

Lazertinib is however a long way behind Tagrisso (osimertinib), AstraZeneca's fast-growing rival in the third-generation category...